***Supplementary table 1.*** *The experimental design.*

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Genotype** | **Used label** | **Tamoxifen administration** | **SARS-CoV-2 infection** | **Sacrificed on the 5th day (n)** | **Sacrificed on the 10th day (n)** | **Deceased on the 5th day (n)** | **Deceased on the 8th day (n)** | **Overall** |
| Rosa-*ACE2* | Rosa-*ACE2* | NO | Infection | 1 | 1 | 0 | 0 | 2 |
| Rosa-*ACE2*Tx | Tx. administration | 6 | 3 | 0 | 0 | 9 |
| UBC-*ACE2* | UBC-*ACE2* | NO | Infection | 1 | 1 | 0 | 0 | 2 |
| UBC-*ACE2*Tx | Tx. administration | 2 | 0 | 5 | 1 | 8 |
| UBC-*ACE2*Tx(Uninfected) | Tx. administration | NO | 1 | 1 |  |  | 2 |
| Wild type | WT | Tx. administration | Infection | 6 | 3 | 0 | 0 | 9 |
| WT(Uninfected) | Tx. administration | NO | 1 | 1 | 0 | 0 | 2 |